FeesSafety
Pluang+

Avalon's Nechalacho Rare Earths Project featured at Canada Investment Summit as key critical minerals opportunity

Market News
15 Sep 2026
Newsfile Corp
View Source
Bullish
Avalon's Nechalacho Rare Earths Project featured at Canada Investment Summit as key critical minerals opportunity

Avalon Advanced Materials' Nechalacho Rare Earths Project in Northwest Territories has been selected for the Canada Investment Summit Prospectus, highlighting it as a strategic critical minerals development opportunity. The project gains exposure to global investors amid growing government focus on secure critical minerals supply chains in North America. Nechalacho is one of Canada's most advanced rare earth assets, with updated technical studies supporting Avalon's plans for development, partnerships, and financing. This inclusion positions the project as a key player in Canada's and North America's critical minerals industry growth.

The Nechalacho Rare Earths Project is highlighted in the Canada Investment Summit Prospectus. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 16, 2026 03:11 WIB: of 32 priced Basic Materials-sector US stocks tradable on Pluang, 7 rose and 25 fell today. Notable price changes include GFI (Gold Fields Limited) at USD 43.00, down 4.66%, SBSW (Sibanye Stillwater Ltd) at USD 11.99, down 4.39%, and LYB (LyondellBasell Industries NV) at USD 65.38, up 4.17%.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
48 minutes ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
48 minutes ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
Ethereum co-founder predicts AI and crypto will merge to enable trusted automated work on blockchain.

Ethereum co-founder predicts AI and crypto will merge to enable trusted automated work on blockchain.

Joseph Lubin, co-founder of Ethereum, predicts that artificial intelligence (AI) and cryptocurrency will merge on the Ethereum blockchain to create a system where automated tasks are commissioned, completed, and paid for with trust guaranteed by bloc...

Protocol Fundamentals
Bullish
4 hours ago
Bitcoin dips near $80K amid lower trading volume and rising exchange reserves, signaling cautious market sentiment.

Bitcoin dips near $80K amid lower trading volume and rising exchange reserves, signaling cautious market sentiment.

Bitcoin's price dropped to around $80,494, down 1.26%, alongside a 14.11% decline in trading volume, indicating weaker market participation. Despite increased network activity and a slight rise in Bitcoin's market dominance, sentiment remained neutra...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App